JANX · Janux Therapeutics Inc
United States · RS rating 83 · As of 2026-10-14
| Price | 17.13 USD |
|---|---|
| 1-day change | -0.3% |
| RS rating (overall / 1M / 3M / 12M) | 83 / 87 / 84 / 19 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 27 / 33 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -30.8% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +50.7% |
| Market cap (USD) | $924.0M |